INTRODUCTION
============

*Brucella* is a facultative intracellular pathogen, a family of small, nonmotile, gram-negative coccobacilli, that causes abortion in domestic animals (sheep, cattle, and goats), and a febrile illness ("undulant fever") in humans ([@b8], [@b9]). In Syria, it affects a large number of animals and an increasing number of cases in humans. The last recommendation by the World Health Organization (WHO) for the treatment of human acute brucellosis in adults suggested 600 to 900 mg rifampicin and 200 mg doxycycline daily for a minimum of 6 weeks, or doxycycline for 6 weeks plus streptomycin for 2--3 weeks ([@b4]). However, the relapse rates associated with doxycycline/ rifampicin and doxycycline/streptomycin regimens are 4.6--24% and 5--8%, respectively ([@b27]).

The combination between the rifampicin and trimethoprim-sulfomethoxazole is the suggested regimen for children ([@b3], [@b15], [@b16]). Triple-antibiotic combinations were found to be of value in some cases of brucellar endocarditis, meningitis, and spondylitis ([@b2], [@b21], [@b31]). Fluoroquinolones are an alternative. Only *in vitro* observations exist for moxifloxacin and levofloxacin ([@b19]), whereas various combinations that incorporate ciprofloxacin and ofloxacin have been tried clinically, yielding similar efficacy to that of the classic regimens ([@b13]). Fluoroquinolones have good anti-brucellosis activity *in vitro* (1, 18, 25) and reach high intracellular concentrations.

*Brucella* isolates are generally considered susceptible to the antibiotics that are recommended by the WHO. Nevertheless, sporadic cases of a kind of antibiotic resistance have been reported ([@b6], [@b19]). The aim of this study is to determine the susceptibility of doxycycline, rifampicin, tetracycline, streptomycin, spiramycin, amoxicillin, flucloxacillin, cefixime, cefprozil, cefotaxime, ceftazidime, cefazolin, ciprofloxacin, levofloxacin, ofloxacin, moxifloxacin and sparfloxacin against the *Brucella* isolates identified in the Laboratory of Molecular Biology and Biotechnology, Atomic Energy Commission, Syria, collected from milk samples over different provinces.

MATERIALS AND METHODS
=====================

Microorganisms and growth conditions
------------------------------------

Eighty nine brucella isolates were collected prospectively between 2004 and 2007 from bovine and ovine milk from different Syrian provinces. Syrian territories were divided into four regions as follows: Northern region (including: Al-Hasakah, Dir-Alzour, Al-Rakah and Aleppo provinces); Central region (including: Edleb, Hama and Homs provinces); Coastal region (including: Tartous and Lattakia provinces) and Southern region (including: Al-Quonaitra, Daraa, Al-Souaida, Damascus and Damascus rural provinces). Bacteria were isolated from milk cultures at the Immunology and Microbiology Laboratory, AECS ([@b5]). *Brucella* was grown under optimal conditions in 2YT agar {Difco, BD, USA (peptone \[10 g\], sodium chloride \[5 g\], meat extract \[5 g\], agar \[20 g\], distilled water \[1 litre\])} at 37°C in a water bath (Grant, Cambridge, UK) to ensure sufficient cell density. Following antibiotics (Oxoid, UK) were added to inhibit the growth of organisms other than *Brucella*, cycloheximide (100 mg), bacitracin (25000 units), polymyxin B sulphate (5000 units), vancomycin (20 mg), nalidixic acid (5 mg) and nystatin (100000 units). To prepare the solid selective media, basal medium was melted and then cooled to 56°C in a water bath and stock solutions of the antibiotics added with 5% of horse serum (PAN-Biotech, Gmbh, Germany). The biotyping of the bacteria used the following tests: CO~2~ requirement, H~2~S production, urease and oxidase positivity, growth in the presence of dyes (thionine and basic fuchsine), and reaction with monospecific anti-A and anti-M sera (Arcomex, Jordan). Strains identified as *B. melitensis* (81 isolates) or *B. abortus* (8 isolates) were stored in 2YT medium at -2**0**°C until susceptibility testing. During the experiment, laboratory workers were wearing impermeable protective clothes, gloves, and face masks.

Antibiotics susceptibility testing
----------------------------------

In order to estimate the antibiotics susceptibility, well broth microdilution method was used with 96-well plates, (TPP, Switzerland). Antibiotics were twofold diluted in Brucella broth^®^ (acumedia^®^, Michigan, USA) and wells were inoculated with 10^6^ CFU of bacteria (in a 0.2 ml final volume). The incubation period was 48 h at 37°C. MIC testing was performed according to the recommendations of the CLSI ([@b22]). Unsupplemented brucella broth media were used. The pH of the broth was adjusted to a range of 7.1 ± 0.1. The range of concentrations assayed for each antibiotic was 0.07 to 100 μg/ml. The lowest concentration that completely inhibited visual growth was recorded and interpreted as the MIC. The absorbance was determined at 590 nm (Thermo-lab Systems Reader, Finland). All tests were performed in triplicate and then averaged.

Investigated antibiotics were the following: doxycycline (Sigma, St. Louis, USA), rifampicin (Sigma), tetracycline (Sigma-Aldrich, USA), streptomycin (Sigma), spiramycin (Sigma), amoxicillin (Fluka, Sigma-Aldrich, USA), flucloxacillin (Square Pharma, Bangladish), cefixime (Fluka, Sigma-Aldrich, USA), cefprozil (Bristol-Myers Squibb, New-York, USA), cefotaxime (Sigma), ceftazidime (Sigma), cefazolin (Fluka, Sigma-Aldrich, USA), ciprofloxacin (Bayer, Istambul, Turkey), levofloxacin (Sigma), ofloxacin (Sigma), moxifloxacin (Bayer, Istambul, Turkey) and sparfloxacin (Sigma).

A well containing no antibiotics was also employed. Plates were incubated in the conditions mentioned above.

RESULTS
=======

The MIC~range~, MIC~50~ and MIC~90~ values of the antibiotics are shown in [Table 1](#tbl1){ref-type="table"}. No activity was observed at all Syrian regions when the following antibiotics were used: streptomycin, spiramycin, amoxicillin, flucloxacillin, cefixime, cefprozil, cefotaxime, ceftazidime, and cefazoline. Almost all the isolates were resistant to these antibiotics. The MIC~range~values of doxycycline and tetracycline were low against the isolates collected from central region (0.3--0.75 μg/ml and 0.15--0.75 μg/ml, respectively), and moderate to high against that collected from the other regions. Whereas, MIC~range~ values of rifampicin were very high against the isolates collected from all regions (from 1.5--6.25 μg/ml against isolates collected from southern and central regions, to 25--50 μg/ml against that collected from northern region. Among the quinolones, ciprofloxacin was the most effective against the isolates collected from all regions (MIC~range~: 0.07--6.25 μg/ml; from 0.07--0.3 μg/ml against isolates collected from northern region to 0.75--6.25 μg/ml against that collected coastal region), and moxifloxacin had the highest MIC~range~. Other than ciprofloxacin, the MIC~range~ of ofloxacin was the lowest, particularly against the isolates collected from northern region (0.07--0.75 μg/ml), but it was moderate to high against that collected from the other regions. Levofloxacin and sparfloxacin had moderate activities against the isolates collected from all regions.

###### 

MICs values of antibiotics against Syrian isolates collected from different regions. Efficacy evaluation of some antibiotics against Syrian *Brucella* spp isolates, *in vitro*. (Safi and AL-Mariri)

                   MICs at (Northern region μg/ml)   MICs at (Coastal region μg/ml)   MICs at (Central region μg/ml)   MICs at (Southern region μg/ml)                                                                               
  ---------------- --------------------------------- -------------------------------- -------------------------------- --------------------------------- --------- --------- ------------ --------- --------- ------------ --------- ---------
                   MIC~range~                        MIC~50~                          MIC~90~                          MIC~range~                        MIC~50~   MIC~90~   MIC~range~   MIC~50~   MIC~90~   MIC~range~   MIC~50~   MIC~90~
  Doxycycline      0.3--6.25                         0.75                             3                                6.25--12.5                        6.25      12.5      0.3--0.75    0.75      0.75      0.75--3      0.75      3
  Rifampicin       25--50                            25                               50                               25--50                            25        50        1.5--3       3         3         1.5--6.25    3         6.25
  Tetracycline     1.5--12.5                         6.25                             12.5                             6.25--12.5                        6.25      12.5      0.15--0.75   0.3       0.75      0.75--6.25   1.5       6.25
  Streptomycin     50-\>100                          100                              \>100                            \>100                             \>100     \>100     \>100        \>100     \>100     50-\>100     100       \>100
  Spiramycin       \>100                             \>100                            \>100                            \>100                             \>100     \>100     \>100        \>100     \>100     \>100        \>100     \>100
  Amoxicillin      \>100                             \>100                            \>100                            \>100                             \>100     \>100     \>100        \>100     \>100     \>100        \>100     \>100
  Flucloxacillin   \>100                             \>100                            \>100                            \>100                             \>100     \>100     \>100        \>100     \>100     \>100        \>100     \>100
  Cefixime         \>100                             \>100                            \>100                            50-\>100                          100       \>100     50-\>100     100       \>100     \>100        \>100     \>100
  Cefprozil        12.5-\>100                        25                               100                              6.25-\>100                        12.5      100       12.5-\>100   25        100       \>100        \>100     \>100
  Cefotaxime       12.5-\>100                        25                               100                              6.25-\>100                        12.5      100       12.5-\>100   25        \>100     \>100        \>100     \>100
  Ceftazidime      25--100                           50                               100                              6.25-\>100                        12.5      100       6.25--100    25        100       \>100        \>100     \>100
  Cefazolin        12.5--50                          12.5                             25                               12.5-\>100                        25        \>100     6.25--50     12.5      25        50-\>100     50        \>100
  Ciprofloxacin    0.07--0.3                         0.07                             0.3                              0.75--6.25                        1.5       3         0.3--0.75    0.75      0.75      0.15--1.5    0.75      1.5
  Levofloxacin     0.75--12.5                        1.5                              6.25                             0.15--25                          0.75      25        0.75--6.25   1.5       3         0.3--6.25    0.75      6.25
  Ofloxacin        0.07--0.75                        0.15                             0.75                             0.15--50                          0.75      25        0.15--12.5   0.75      6.25      0.3--6.25    0.75      3
  Moxifloxacin     0.75--50                          6.25                             50                               12.5--100                         25        100       1.5--50      12.5      50        12.5--100    25        \>100
  Sparfloxacin     0.15--12.5                        0.75                             12.5                             1.5--100                          3         50        0.15--12.5   0.3       6.25      3--12.5      6.25      12.5

DISCUSSION
==========

Treatment of human brucellosis needs antibiotics that can penetrate macrophages and can act in the acidic intracellular environment. *Brucella* is considered to be susceptible to the antibiotics recommended by the WHO for treatment of brucellosis. Relapses, at a rate of about 10 percent, usually occur in the first year after the infection, but they are caused in most cases by inadequate treatment ([@b24]). Strains resistant to the main antimicrobial agents may emerge and lead on to treatment inhibition ([@b20]).

The isolates included in this work were collected from different areas of Syrian cities. They were totally resistant against streptomycin, macrolide (spiramycin), amoxicillin, flucloxacillin, and against all cephalosporins used in this work (including: cefixime, cefprozil, cefotaxime, ceftazidime, and cefazolin). This result did not concord, in part, with that found by Palenque *et al.* ([@b23]); where they found that cefotaxime was among the most effective agents tested, with MICs ranging from 0.25 to 2 μg/ml. However, it concords with the result of ceftazidime where the MICs was between 4 and 64 μg/ml.

All the isolates were susceptible to tetracycline, the MIC~range~ of this antibiotic was very low, particularly against the isolates collected from the central region (0.15--0.75 μg/ml). This finding agrees with previous reports ([@b6], [@b7], [@b16], [@b30]).

In addition, doxycyline had a very good activity against all isolates, with a MIC~range~ of 0.3--0.75 μg/ml in the coastal region; whereas, rifampicin showed a very low activity against almost all isolates. On the other hand, eleven isolates were totally resistant to rifampicin. This finding did not agree with that found by Turkmani *et al.* ([@b29]). However, Baykam *et al.* ([@b6]) and Dimitrov *et al.* ([@b10]) found that 9.6% and 8% of the isolates were resistant to rifampicin *in vitro*, respectively.

Most studies that examined the use of quinolones against *B. melitensis* showed, generally, low MICs values; where the MIC~90~ to the ofloxacin was 0.02--2.5 mg/l ([@b11], [@b14], [@b17]); to the levofloxacin 0.5 mg/l ([@b17], [@b28]); to the sparfloxacin 0.12--2 mg/l ([@b11], [@b12], [@b26]); to the ciprofloxacin 0.06--2 mg/l ([@b7], [@b17], [@b19]); and to the moxifloxacin 0.5--1 mg/l ([@b19], [@b28]). However, among the quinolones that are used in our study, ciprofloxacin revealed the lowest MIC~range~ against the isolates collected from all Syrian regions (MIC~range~ 0.07--6.25 μg/ml), and moxifloxacin showed the highest MIC~range~ (MIC~range~ 1.5--100 μg/ml).

In conclusion, among the antibiotics used in this study, quinolones were the most effective agents against Syrian brucella isolates. Ciprofloxacin and ofloxacin showed a very good activity; sparfloxacin and levofloxacin were quite active, whereas, moxifloxacin had limited effects. Further and more specific studies, *in vivo*, are much recommended to determine the efficacy of quinolones in the treatment of brucellosis infections.

On the other hand, doxycycline and tetracycline had a quite good activity. Since rifampicin is commonly used for prevalent diseases such as tuberculosis, the regional susceptibility pattern of rifampicin should be assessed periodically.

Spiramycin, amoxicillin and cephalosporins were included in this study for research purposes only, as those agents are ineffective *in vivo* for brucellosis treatment.
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